Helius Extends its Patient Therapy Access Program (PTAP), Bringing the Benefits of its PoNS® Device to More People with Multiple Sclerosis
Excerpt from the Press Release:
PTAP Lowers the Cost of PoNS Therapy™ for Qualified Americans
NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS®) into the hands of qualified Americans with multiple sclerosis (MS) at a significantly reduced cost.
This initiative, the Patient Therapy Access Program (PTAP), launched in June 2022 and was slated to expire at the end of last year. PTAP is now active until June 30, 2023, reflecting high interest in a program that partially subsidizes PoNS Therapy™ for people with MS who qualify through a proper prescription and letter of medical necessity.
At the center of PoNS Therapy is Helius’s PoNS device, which delivers electrical impulses through nerve fibers on the tongue, stimulating the flow of neural impulses to areas of the brain that control gait. This creates a cascade of activity resulting in neuroplastic changes – essentially “rewiring” parts of the brain associated with walking. When paired with an exercise regimen supervised by a rehabilitation specialist, this activity improves gait impairment in people with MS.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?